The U.S. Food and Drug Administration said on Tuesday certain samples of sitagliptin, a compound in Merck’s diabetes drug Januvia, were contaminated with a possible carcinogen.
The agency said it would not object to the temporary distribution of sitagliptin containing the impurity above the acceptable intake limit to avoid a shortage.
